Analysts think EXEL stock price could decrease by -3%
Jun 05, 2025, 11:25 AM
9.30%
What does EXEL do
Exelixis, an oncology company based in Alameda, California, focuses on developing treatments for difficult-to-treat cancers, with four marketed products including cabozantinib for various cancers. Founded in 2000, it employs 1,310 people.
21 analysts think EXEL stock price will decrease by -3.37%. The current median analyst target is $40.80 compared to a current stock price of $42.23. The lowest analysts target is $29.29 and the highest analyst target is $58.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
